Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B5ee9eedfbb6f16df0f6a0811a0a77cb7> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B5ee9eedfbb6f16df0f6a0811a0a77cb7 NCIT_P378 "NCI" @default.
- B5ee9eedfbb6f16df0f6a0811a0a77cb7 type Axiom @default.
- B5ee9eedfbb6f16df0f6a0811a0a77cb7 annotatedProperty IAO_0000115 @default.
- B5ee9eedfbb6f16df0f6a0811a0a77cb7 annotatedSource NCIT_C113787 @default.
- B5ee9eedfbb6f16df0f6a0811a0a77cb7 annotatedTarget "An inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. PFKFB3, an enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, is highly expressed and active in human cancer cells; it plays a key role in increasing both glycolytic flux in and proliferation of cancer cells." @default.